A startup developing allogeneic T-cell therapies from pluripotent stem cells to provide novel treatments for advanced and recurrent cancers and immune-related diseases. Aiming to deliver the potential for a cure to diseases that were previously difficult to treat.
Solving challenges in manufacturing, construction, and infrastructure with proprietary AI that leverages even limited data. A startup supporting operational efficiency and labor savings, aiming for a future where humans and AI coexist.
A startup providing the “mui Smart Living” platform for smart homes. It supports corporate digital transformation with user-friendly UI/UX and compliance with standard specifications, contributing to enhanced customer experiences in the energy and housing sectors.
A startup has developed a painless, simple test using tears to detect cancer early and monitor for recurrence. Using cutting-edge technology originating from Kobe University, it enables highly sensitive detection of extracellular vesicles, allowing testing in everyday settings like homes or pharmacies.
Tellme's original business was operating hair salons. Over years of observing changes in their clientele, and as a service for customers who could no longer visit the salon due to illness or aging, the company developed a technology to assess the risk of glycation (a measure of aging) through hair analysis. This technology is currently being promoted as a diabetes screening technology. After being featured at the World Expo, it gained significant attention from overseas countries and institutions for its ability to assess risk without the need for blood sampling. In Japan, the technology is also seen as contributing to behavioral change among the segment of the population indifferent to their own health (kenko mukanshinsō) within local municipalities. Tellme is now pursuing the commercialization of this service as a means of optimizing social security costs.